Your browser doesn't support javascript.
loading
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Castillo, Jorge J; Abeykoon, Jithma P; Gustine, Joshua N; Zanwar, Saurabh; Mein, Kirsten; Flynn, Catherine A; Demos, Maria G; Guerrera, Maria L; Kofides, Amanda; Liu, Xia; Munshi, Manit; Tsakmaklis, Nickolas; King, Rebecca; Yang, Guang; Hunter, Zachary R; Advani, Ranjana H; Palomba, Maria Lia; Ansell, Stephen M; Gertz, Morie A; Kapoor, Prashant; Treon, Steven P.
Afiliação
  • Castillo JJ; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Abeykoon JP; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Gustine JN; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Zanwar S; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Mein K; Department of Medicine, Boston University Medical School, Boston, MA, USA.
  • Flynn CA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Demos MG; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Guerrera ML; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Kofides A; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Liu X; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Munshi M; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tsakmaklis N; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • King R; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Yang G; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hunter ZR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Advani RH; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Palomba ML; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ansell SM; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Gertz MA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kapoor P; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Treon SP; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Br J Haematol ; 192(3): 542-550, 2021 02.
Article em En | MEDLINE | ID: mdl-33207010
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Adenina / Macroglobulinemia de Waldenstrom / Inibidores de Proteínas Quinases Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Adenina / Macroglobulinemia de Waldenstrom / Inibidores de Proteínas Quinases Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article